Want to see WHWK full AI Analyst Report?
Total Valuation
Whitehawk Therapeutics has a market cap or net worth of $212.98M. The enterprise value is $173.90M.
Market Cap$212.98M
Enterprise Value$173.90M
Share Statistics
Whitehawk Therapeutics has 53,783,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,783,330
Owned by Insiders19.23%
Owned by Institutions54.25%
Financial Efficiency
Whitehawk Therapeutics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -83.93%.
Return on Equity (ROE)-0.15
Return on Assets (ROA)-0.14
Return on Invested Capital (ROIC)-83.93%
Return on Capital Employed (ROCE)-0.84
Revenue Per Employee246.38K
Profits Per Employee-710.21K
Employee Count29
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Whitehawk Therapeutics is ―. Whitehawk Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio20.96
PB Ratio1.10
Price to Fair Value1.10
Price to FCF-1.53
Price to Operating Cash Flow-2.48
PEG Ratio0.09
Income Statement
In the last 12 months, Whitehawk Therapeutics had revenue of 7.14M and earned -20.60M in profits. Earnings per share was -0.33.
Revenue7.14M
Gross Profit6.38M
Operating Income-114.40M
Pretax Income-20.60M
Net Income-20.60M
EBITDA-20.52M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was -107.78M and capital expenditures -1.00K, giving a free cash flow of -107.78M billion.
Operating Cash Flow-107.78M
Free Cash Flow-107.78M
Free Cash Flow per Share-2.00
Dividends & Yields
Whitehawk Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.06
52-Week Price Change95.94%
50-Day Moving Average4.27
200-Day Moving Average3.16
Relative Strength Index (RSI)42.99
Average Volume (3m)3.35M
Important Dates
Whitehawk Therapeutics upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Whitehawk Therapeutics as a current ratio of 10.26, with Debt / Equity ratio of 0.00%
Current Ratio10.26
Quick Ratio10.26
Debt to Market Cap0.00
Net Debt to EBITDA1.83
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Whitehawk Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Whitehawk Therapeutics EV to EBITDA ratio is -5.47, with an EV/FCF ratio of -1.15.
EV to Sales15.70
EV to EBITDA-5.47
EV to Free Cash Flow-1.15
EV to Operating Cash Flow-1.15
Balance Sheet
Whitehawk Therapeutics has $123.04M in cash and marketable securities with $0.00 in debt, giving a net cash position of $123.04M billion.
Cash & Marketable Securities$123.04M
Total Debt$0.00
Net Cash$123.04M
Net Cash Per Share$2.29
Tangible Book Value Per Share$2.20
Margins
Gross margin is 0.00%, with operating margin of -1601.12%, and net profit margin of -288.26%.
Gross Margin0.00%
Operating Margin-1601.12%
Pretax Margin-288.26%
Net Profit Margin-288.26%
EBITDA Margin-287.15%
EBIT Margin-288.26%
Analyst Forecast
The average price target for Whitehawk Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside94.65% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast-1124.16%